Zai Lab ADR had its Relative Strength (RS) Rating upgraded from 89 to 92 Tuesday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
History shows that the best stocks tend to have an 80 or better RS Rating in the early stages of their moves.
Zai Lab ADR is not currently near a potential buy zone. See if the stock goes on to form a base that could spark a new run.
Zai Lab ADR showed 0% earnings growth in the latest quarterly report, while sales growth came in at 22%.
The company earns the No. 82 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
